{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:51:39Z","timestamp":1789649499825,"version":"4.0.0"},"reference-count":23,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Otolaryngol Head Neck Surg"],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Cutaneous squamous cell carcinoma is a common cancer, and approximately 5% of cases present with high-risk features, such as regional nodal metastases. Postoperative radiotherapy (PORT) improves outcomes in this group, but the TROG 05.01 trial found no added benefit of concurrent chemotherapy. Identification of patients with poor disease-free survival (DFS) is critical to optimize future adjuvant treatment strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To identify a subgroup of patients with poor DFS following PORT with or without concurrent chemotherapy who may be appropriate candidates for future adjuvant trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This was a secondary analysis of the prospective, randomized phase 3 TROG 05.01 trial, which enrolled 321 patients with high-risk cutaneous squamous cell carcinoma of the head and neck between April 2005 and July 2014 at multiple centers in Australia. Data were analyzed in January 2025. A recursive partitioning analysis using classification and regression trees was applied to identify prognostic subgroups. Disease-free and overall survival (OS) were measured from randomization until relapse or death, with appropriate censoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary outcome was DFS; secondary outcomes included OS and identification of prognostic subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 321 patients randomized, 310 (23 female individuals [7%] and 287 male individuals [93%]; median [range] age, 64 [32-85] years) initiated the allocated treatment. The recursive partitioning analysis identified 6 nodes and grouped patients into 3 DFS risk categories. A high-risk group (n\u2009=\u200988) was defined by the presence of extranodal extension and a nodal size of 22 mm or greater. This group had 5-year DFS and OS rates of 56% (95% CI, 45%-66%) and 59% (95% CI, 46%-69%), respectively, compared with 75% (95% CI, 68%-81%) and 85% (95% CI, 79%-90%) in the non\u2013high-risk group. The hazard ratios for high vs non\u2013high risk were 2.0 for DFS (95% CI, 1.3-3.1;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.001) and 3.2 for OS (95% CI, 1.9-5.3;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>The results of this secondary analysis suggest that patients with extranodal extension and a nodal size of 22 mm or greater represent a high-risk subgroup with inferior DFS following PORT with or without concurrent chemotherapy. These patients may benefit from future trials that evaluate adjuvant treatment intensification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT00193895?term=NCT00193895&amp;amp;amp;rank=1\">NCT00193895<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaoto.2025.2110","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T15:31:03Z","timestamp":1756395063000},"page":"938","source":"Crossref","is-referenced-by-count":7,"title":["Prognostic Subgroups for Disease-Free Survival With Cutaneous Squamous Cell Carcinoma of the Head and Neck"],"prefix":"10.1001","volume":"151","author":[{"given":"Sandro Virgilio","family":"Porceddu","sequence":"first","affiliation":[{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia"},{"name":"Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Connolly","sequence":"additional","affiliation":[{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia"},{"name":"Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Bressel","sequence":"additional","affiliation":[{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia"},{"name":"Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Wratten","sequence":"additional","affiliation":[{"name":"Calvary Mater Newcastle, New South Wales, Australia"},{"name":"University of Newcastle, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard Yu-hao","family":"Liu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Queensland, Queensland, Australia"},{"name":"Department of Radiation Oncology, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Rischin","sequence":"additional","affiliation":[{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia"},{"name":"Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"ooi250043r1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.jaad.2012.11.037","article-title":"Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012.","volume":"68","author":"Karia","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"ooi250043r2","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/S1470-2045(08)70178-5","article-title":"Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study.","volume":"9","author":"Brantsch","year":"2008","journal-title":"Lancet Oncol"},{"issue":"7","key":"ooi250043r3","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/hed.21574","article-title":"Outcome of patients treated surgically for lymph node metastases from cutaneous squamous cell carcinoma of the head and neck.","volume":"33","author":"Givi","year":"2011","journal-title":"Head Neck"},{"issue":"29","key":"ooi250043r4","doi-asserted-by":"publisher","first-page":"3338","DOI":"10.1200\/JCO.2014.60.7333","article-title":"Nonmelanoma cutaneous head and neck cancer and Merkel cell carcinoma: current concepts, advances, and controversies.","volume":"33","author":"Porceddu","year":"2015","journal-title":"J Clin Oncol"},{"issue":"10","key":"ooi250043r5","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1097\/00005537-200310000-00031","article-title":"Cutaneous head and neck squamous cell carcinoma metastatic to cervical lymph nodes (nonparotid): a better outcome with surgery and adjuvant radiotherapy.","volume":"113","author":"Veness","year":"2003","journal-title":"Laryngoscope"},{"issue":"5","key":"ooi250043r6","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/hed.24692","article-title":"Node-positive cutaneous squamous cell carcinoma of the head and neck: Survival, high-risk features, and adjuvant chemoradiotherapy outcomes.","volume":"39","author":"Amoils","year":"2017","journal-title":"Head Neck"},{"issue":"11","key":"ooi250043r7","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1002\/hed.21965","article-title":"Predictors of outcome in patients with metastatic cutaneous head and neck squamous cell carcinoma involving cervical lymph nodes: Improved survival with the addition of adjuvant radiotherapy.","volume":"34","author":"Wang","year":"2012","journal-title":"Head Neck"},{"issue":"9","key":"ooi250043r8","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1002\/cncr.24208","article-title":"Metastatic cutaneous squamous cell carcinoma of the head and neck: the Immunosuppression, Treatment, Extranodal Spread, and Margin Status (ITEM) prognostic score to predict outcome and the need to improve survival.","volume":"115","author":"Oddone","year":"2009","journal-title":"Cancer"},{"issue":"9","key":"ooi250043r9","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1046\/j.1445-2197.2003.02737.x","article-title":"Metastatic cutaneous squamous cell carcinoma to the parotid: the role of surgery and adjuvant radiotherapy to achieve best outcome.","volume":"73","author":"Dona","year":"2003","journal-title":"ANZ J Surg"},{"issue":"14","key":"ooi250043r10","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/j.ejca.2015.06.110","article-title":"Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline.","volume":"51","author":"Stratigos","year":"2015","journal-title":"Eur J Cancer"},{"issue":"13","key":"ooi250043r11","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2017.77.0941","article-title":"Postoperative concurrent chemoradiotherapy versus postoperative radiotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck: the randomized phase III TROG 05.01 trial.","volume":"36","author":"Porceddu","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"ooi250043r12","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1046\/j.1440-1673.2001.01030.x","article-title":"Parotid lymph-node metastases from cutaneous squamous-cell carcinomas: treatment outcome and prognostic factors following surgery and adjuvant radiotherapy.","volume":"46","author":"Chua","year":"2002","journal-title":"Australas Radiol"},{"issue":"7","key":"ooi250043r13","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1002\/hed.20576","article-title":"Cutaneous head and neck squamous cell carcinoma metastatic to parotid and cervical lymph nodes.","volume":"29","author":"Veness","year":"2007","journal-title":"Head Neck"},{"issue":"5","key":"ooi250043r14","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1002\/hed.25066","article-title":"Lymph node ratio as a prognostic factor in metastatic cutaneous head and neck squamous cell carcinoma.","volume":"40","author":"Vasan","year":"2018","journal-title":"Head Neck"},{"issue":"6","key":"ooi250043r15","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/hed.23982","article-title":"Outcomes after surgery and postoperative radiotherapy for perineural spread of head and neck cutaneous squamous cell carcinoma.","volume":"38","author":"Warren","year":"2016","journal-title":"Head Neck"},{"issue":"5","key":"ooi250043r16","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/hed.20991","article-title":"Radiotherapy for perineural invasion in cutaneous head and neck carcinomas: toward a risk-adapted treatment approach.","volume":"31","author":"Jackson","year":"2009","journal-title":"Head Neck"},{"issue":"4","key":"ooi250043r17","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1001\/jamaoto.2018.4515","article-title":"Outcomes of cutaneous squamous cell carcinoma in the head and neck region with regional lymph node metastasis: a systematic review and meta-analysis.","volume":"145","author":"Sahovaler","year":"2019","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"4","key":"ooi250043r18","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma.","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"ooi250043r19","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002757","article-title":"Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis.","volume":"9","author":"Rischin","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"17","key":"ooi250043r21","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJMoa2209813","article-title":"Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma.","volume":"387","author":"Gross","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"ooi250043r23","doi-asserted-by":"publisher","first-page":"S136","DOI":"10.1016\/j.ijrobp.2023.06.541","article-title":"Addition of metastasis-directed therapy to standard of care systemic therapy for oligometastatic breast cancer (EXTEND): a multicenter, randomized phase II trial.","volume":"117","author":"Reddy","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ooi250043r20","unstructured":"Regeneron. Adjuvant Libtayo (cemiplimab) significantly improves disease-free survival (DFS) after surgery in high-risk cutaneous squamous cell carcinoma (CSCC) in phase 3 trial. Accessed January 13, 2025. https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/adjuvant-libtayor-cemiplimab-significantly-improves-disease-free"},{"key":"ooi250043r22","unstructured":"National Cancer Institute. Testing the addition of an immunotherapy drug, cemiplimab (REGN2810), plus surgery to the usual surgery alone for treating advanced skin cancer. Accessed May 1, 2025. https:\/\/clinicaltrials.gov\/study\/NCT06568172."}],"container-title":["JAMA Otolaryngology\u2013Head &amp; Neck Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/articlepdf\/2838131\/jamaotolaryngology_porceddu_2025_oi_250043_1759347484.05204.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T15:00:33Z","timestamp":1760022033000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/fullarticle\/2838131"}},"subtitle":["A Secondary Analysis of a Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoto.2025.2110","relation":{},"ISSN":["2168-6181"],"issn-type":[{"value":"2168-6181","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,1]]}}}